Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
164 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Allergic Rhinitis - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Allergic Rhinitis - Pipeline Review, H2 2014', provides an overview of the Allergic Rhinitis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Allergic Rhinitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhinitis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Allergic Rhinitis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Allergic Rhinitis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Allergic Rhinitis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Allergic Rhinitis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Allergic Rhinitis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Allergic Rhinitis Overview 8 Therapeutics Development 9 Pipeline Products for Allergic Rhinitis - Overview 9 Pipeline Products for Allergic Rhinitis - Comparative Analysis 10 Allergic Rhinitis - Therapeutics under Development by Companies 11 Allergic Rhinitis - Therapeutics under Investigation by Universities/Institutes 14 Allergic Rhinitis - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Allergic Rhinitis - Products under Development by Companies 18 Allergic Rhinitis - Products under Investigation by Universities/Institutes 21 Allergic Rhinitis - Companies Involved in Therapeutics Development 22 Johnson & Johnson 22 Shionogi & Co., Ltd. 23 GlaxoSmithKline plc 24 Nektar Therapeutics 25 BioTech Tools 26 Sumitomo Dainippon Pharma Co., Ltd. 27 Novartis AG 28 ALK-Abello A/S 29 Mitsubishi Tanabe Pharma Corporation 30 Revance Therapeutics, Inc. 31 Ligand Pharmaceuticals, Inc. 32 3M Drug Delivery Systems 33 Hisamitsu Pharmaceutical Co., Inc. 34 Stallergenes S.A. 35 Allergopharma Joachim Ganzer KG 36 AnaptysBio, Inc. 37 Oxagen Limited 38 Axikin Pharmaceuticals, Inc. 39 Rottapharm SpA 40 Xencor, Inc. 41 ELORAC, Inc. 42 VentiRx Pharmaceuticals, Inc. 43 Laboratorios LETI S.L. 44 Celsus Therapeutics Plc 45 KAEL-GemVax Co., Ltd. 46 GlycoMar Limited 47 Trimel BioPharma SRL 48 Fountain Biopharma Inc. 49 NeoPharm Co., Ltd. 50 Protectimmun GmbH 51 Panmira Pharmaceuticals, LLC. 52 Ziarco Pharma Ltd 53 Allergic Rhinitis - Therapeutics Assessment 54 Assessment by Monotherapy Products 54 Assessment by Combination Products 55 Assessment by Target 56 Assessment by Mechanism of Action 59 Assessment by Route of Administration 62 Assessment by Molecule Type 64 Drug Profiles 66 Actair - Drug Profile 66 allergenic pollen extract of timothy - Drug Profile 68 bepotastine besylate - Drug Profile 69 MK-8237 - Drug Profile 71 Olea Europaea Pollen Extract - Drug Profile 73 Depigoid Birch - Drug Profile 74 andolast - Drug Profile 75 rPhleum - Drug Profile 76 AVANZ Olive Immunotherapy for Allergic Rhinitis - Drug Profile 77 RT-001 - Drug Profile 78 OC-459 - Drug Profile 80 MRX-4 - Drug Profile 82 rBet v1 - Drug Profile 84 S-555739 - Drug Profile 86 Actair - Drug Profile 87 Dermatophagoides Pteronyssinus Allergen Extract - Drug Profile 89 gpASIT + TM - Drug Profile 90 fevipiprant - Drug Profile 92 GSK-2245035 - Drug Profile 94 SUN-0597 - Drug Profile 96 HP-3060 - Drug Profile 98 levocabastine hydrochloride - Drug Profile 99 (fluticasone furoate + levocabastine hydrochloride) - Drug Profile 100 cidoxepin hydrochloride - Drug Profile 101 DSP-3025 - Drug Profile 102 AM-461 - Drug Profile 104 budesonide - Drug Profile 105 AM-211 - Drug Profile 106 XmAb-7195 - Drug Profile 108 SUN-0597 - Drug Profile 109 esketamine - Drug Profile 111 NKTR-125 - Drug Profile 112 tertomotide - Drug Profile 113 Drug for Japanese Cedar Pollen Allergy - Drug Profile 115 OC-2417 - Drug Profile 116 TA-270 - Drug Profile 117 NPB-3 - Drug Profile 119 ZPL-868087 - Drug Profile 120 Lactococcus lactis G121 - Drug Profile 121 Arabinogalactan - Drug Profile 122 Small Molecule to Antagonize G Protein Coupled Receptors for Respiratory Disorders - Drug Profile 123 VTX-378 - Drug Profile 124 Small Molecules to Inhibit Histamine H3 Receptor for Nasal Congestion and Allergic Rhinitis - Drug Profile 125 FB-825 - Drug Profile 126 GLY-145 - Drug Profile 127 SUNL-731 - Drug Profile 128 ANB-020 - Drug Profile 129 Vaccine for Allergic Rhinitis and Allergic Asthama - Drug Profile 130 854-A - Drug Profile 131 Small Molecule for Allergic Rhinitis - Drug Profile 132 TBS-6 - Drug Profile 133 Small Molecules to Inhibit Spleen Tyrosine Kinase for Allergic Inflammatory Disorders - Drug Profile 134 GLY-079 - Drug Profile 135 rE58 - Drug Profile 136 Small Molecule to Inhibit PGD2 Synthase for Asthma and Allergic Rhinitis - Drug Profile 137 Allergic Rhinitis - Recent Pipeline Updates 138 Allergic Rhinitis - Dormant Projects 150 Allergic Rhinitis - Discontinued Products 151 Allergic Rhinitis - Product Development Milestones 152 Featured News & Press Releases 152 Appendix 159 Methodology 159 Coverage 159 Secondary Research 159 Primary Research 159 Expert Panel Validation 159 Contact Us 160 Disclaimer 160
List of Tables Number of Products under Development for Allergic Rhinitis, H2 2014 13 Number of Products under Development for Allergic Rhinitis - Comparative Analysis, H2 2014 14 Number of Products under Development by Companies, H2 2014 16 Number of Products under Development by Companies, H2 2014 (Contd..1) 17 Number of Products under Investigation by Universities/Institutes, H2 2014 18 Comparative Analysis by Late Stage Development, H2 2014 19 Comparative Analysis by Clinical Stage Development, H2 2014 20 Comparative Analysis by Early Stage Development, H2 2014 21 Products under Development by Companies, H2 2014 22 Products under Development by Companies, H2 2014 (Contd..1) 23 Products under Development by Companies, H2 2014 (Contd..2) 24 Products under Investigation by Universities/Institutes, H2 2014 25 Allergic Rhinitis - Pipeline by Johnson & Johnson, H2 2014 26 Allergic Rhinitis - Pipeline by Shionogi & Co., Ltd., H2 2014 27 Allergic Rhinitis - Pipeline by GlaxoSmithKline plc, H2 2014 28 Allergic Rhinitis - Pipeline by Nektar Therapeutics, H2 2014 29 Allergic Rhinitis - Pipeline by BioTech Tools, H2 2014 30 Allergic Rhinitis - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 31 Allergic Rhinitis - Pipeline by Novartis AG, H2 2014 32 Allergic Rhinitis - Pipeline by ALK-Abello A/S, H2 2014 33 Allergic Rhinitis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 34 Allergic Rhinitis - Pipeline by Revance Therapeutics, Inc., H2 2014 35 Allergic Rhinitis - Pipeline by Ligand Pharmaceuticals, Inc., H2 2014 36 Allergic Rhinitis - Pipeline by 3M Drug Delivery Systems, H2 2014 37 Allergic Rhinitis - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H2 2014 38 Allergic Rhinitis - Pipeline by Stallergenes S.A., H2 2014 39 Allergic Rhinitis - Pipeline by Allergopharma Joachim Ganzer KG, H2 2014 40 Allergic Rhinitis - Pipeline by AnaptysBio, Inc., H2 2014 41 Allergic Rhinitis - Pipeline by Oxagen Limited, H2 2014 42 Allergic Rhinitis - Pipeline by Axikin Pharmaceuticals, Inc., H2 2014 43 Allergic Rhinitis - Pipeline by Rottapharm SpA, H2 2014 44 Allergic Rhinitis - Pipeline by Xencor, Inc., H2 2014 45 Allergic Rhinitis - Pipeline by ELORAC, Inc., H2 2014 46 Allergic Rhinitis - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2014 47 Allergic Rhinitis - Pipeline by Laboratorios LETI S.L., H2 2014 48 Allergic Rhinitis - Pipeline by Celsus Therapeutics Plc, H2 2014 49 Allergic Rhinitis - Pipeline by KAEL-GemVax Co., Ltd., H2 2014 50 Allergic Rhinitis - Pipeline by GlycoMar Limited, H2 2014 51 Allergic Rhinitis - Pipeline by Trimel BioPharma SRL, H2 2014 52 Allergic Rhinitis - Pipeline by Fountain Biopharma Inc., H2 2014 53 Allergic Rhinitis - Pipeline by NeoPharm Co., Ltd., H2 2014 54 Allergic Rhinitis - Pipeline by Protectimmun GmbH, H2 2014 55 Allergic Rhinitis - Pipeline by Panmira Pharmaceuticals, LLC., H2 2014 56 Allergic Rhinitis - Pipeline by Ziarco Pharma Ltd, H2 2014 57 Assessment by Monotherapy Products, H2 2014 58 Assessment by Combination Products, H2 2014 59 Number of Products by Stage and Target, H2 2014 62 Number of Products by Stage and Mechanism of Action, H2 2014 65 Number of Products by Stage and Route of Administration, H2 2014 67 Number of Products by Stage and Molecule Type, H2 2014 69 Allergic Rhinitis Therapeutics - Recent Pipeline Updates, H2 2014 142 Allergic Rhinitis - Dormant Projects, H2 2014 154 Allergic Rhinitis - Discontinued Products, H2 2014 155
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
